The trajectory of Sildenafil presents a intricate picture for shareholders. While the initial launch generated massive gains, the end of its patent opened the avenue to cheaper versions, dramatically eroding sales. https://mysocialguides.com/story7146365/the-copyright-and-the-pharmaceutical-industry-a-risky-opportunity